## 1 Inherited Retinal Dystrophies
\begin{table}
\begin{tabular}{c|c|c|c|c|c|c|c|c|c|c|c} \multicolumn{10}{11}{**Autosomal Dominant IRDs**} \\ \hline \multicolumn{1}{c|}{} & \multicolumn{1}{c|}{**PRDM13**} & \multicolumn{1}{c|}{**RCR**} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} & \multicolumn{1}{c|}{_TEAD1_} \\ \hline Cone-(red) dystrophy & _APPL1_ & _APPL1_ & _APPL3_ & _GUC1A1_ & _GUC2D_ & _PITPN3_ & _PROMI_ & _PROMI_ & _PROH2_ & _RINS1_ & _SEMMA_ & _UNC119_ \\ \hline LCA & _CR3_ & _OR4_ & _OTX2_ & _OTX2_ & _OTX2_ & _OTX4_ & _FSCN2_ & _GUC1A1_ & _HMC1_ & _IMPC1_ & _OTX2_ \\ \hline \multirow{3}{*}{\begin{tabular}{c} Macular dystrophy \\ \end{tabular} } & _PERMI1_ & _CIOTN15_ & _CTNA14_ & _FEMP1_ & _ELOV14_ & _FSCN2_ & _GUC1A1_ & _HMC1_ & _IMPC1_ & _OTX2_ \\ \cline{2-11}  & _PRDM13_ & _PROMI_ & _PROH2_ & _RPH12_ & _TMP3_ & _TR3_ & _TR3_ & _TR3_ & _TR3_ & _TR3_ \\ \hline \multirow{3}{*}{RP} & _AD1_ & _APPL3_ & _RBS17_ & _CAA4_ & _CR3_ & _FSCN2_ & _GUC1A1_ & _HR1_ & _KR11_ & _KR11_ \\ \cline{2-11}  & _NR25_ & _NR26_ & _RPH3_ & _PRF4_ & _PRF4_ & _PRF5_ & _PRF31_ & _TR3_ & _TR3_ & _TR3_ & _TR3_ \\ \cline{2-11}  & _ROMI_ & _NJ1_ & _RP_ & _RPH56_ & _SAG_ & _SEMMA4A_ & _SNRN200_ & _SPP2_ & _TOPORS_ & _TR3_ & _TR3_ & _TR3_ \\ \hline \multirow{3}{*}{\begin{tabular}{c} Cone-(red) dystrophy \\ \end{tabular} } & _ARC4_ & _ADAM9_ & _AT6_ & _CIOT2D_ & _GCP2D_ & _GCP2D_ & _CAC1A2D4_ & _CD1R1_ & _CERKL_ & _CNC43_ & _CNC63_ \\ \cline{2-11}  & _CNN4_ & _GNA72_ & _HTS1_ & _KCNV2_ & _PD6C6_ & _PD6H_ & _FOC1B_ & _RA82_ & _RAX2_ & _RDHS_ \\ \hline \multirow{3}{*}{\
\begin{tabular}{c} Cone-(red) dystrophy \\ \end{tabular} } & _RRRR1 PI_ & _TTL5_ & _CARP4_ & _CCT2_ & _CEP290_ & _CLLIAP1_ & _CRR1_ & _TR3_ & _DTHD1_ & _GDF6_ & _GUC2D_ \\ \cline{2-11}  & _HT10_ & _IQCB1_ & _KCNV13_ & _LCAS_ & _LKAT_ & _NMNATI_ & _PRF4_ & _RD3_ & _RDH2_ & _RFG5_ \\ \cline{2-11}  & _RRRR1 PI_ & _SPTA2_ & _TULP1_ & _TULP2_ & & & & & & & & \\ \hline \multirow{3}{*}{
\begin{tabular}{c} Macular dystrophy \\ \end{tabular} } & _ARC4_ & _CH1_ & _DRAM2_ & _IMPC1_ & _MSDS_ & _TR3_ & _TR3_ & _TR3_ & _TR3_ & _TR3_ \\ \cline{2-11}  & _ARC4_ & _AGLS_ & _ARGLE78_ & _ARL6_ & _ARL2B_ & _BBS1_ & _BBS2_ & _BBS1_ & _C20r71_ & _C80r37_ \\ \cline{2-11}  & _CERKL_ & _CICR1_ & _NCSC1A1_ & _CNCN6B1_ & _CRR1_ & _CTV42_ & _DHDDS_ & _DH38_ & _ENCI_ & _L5_ \\ \cline{2-11}  & _FAM16 IA_ & _CP125_ & _HCSC1A1_ & _ID13B_ & _HT140_ & _HT117_ & _IMPC2_ & _KLA154_ & _K2_ & _LKAT_ \\ \cline{2-11}  & _MAK_ & _METK_ & _MVK_ & _NEX2_ & _NULK01_ & _NR23_ & _NRL0_ & _PD6A_ & _PD6 EB_ & _PD6 EB_ \\ \cline{2-11}  & _POMCNT1_ & _PRCD_ & _PROMI_ & _RBP3_ & _REEP6_ & _RGR_ & _MT2_ & _RR1P1_ & _RR1P1_ \\ \cline{2-11}  & _BRPES_ & _SAG_ & _SAMD11_ & _SLCA14_ & _SPTA2_ & _TRNT1_ & _TTCS_ & _TULP1_ & _USH2A_ & _ZN7408_ \\ \hline \multicolumn{11}{l}{_ZN513_} & \multicolumn{1}{c|}{_SADD11_} & \multicolumn{1}{c|}{_SLCA14_} & \multicolumn{1}{c|}{_SPLTA2_} & \multicolumn{1}{c|}{_TRNT1_} & \multicolumn{1}{c|}{_TTCS_} & \multicolumn{1}{c|}{_TULP1_} & \multicolumn{1}{c|}{_USH2A_} & \multicolumn{1}{c|}{_ZN7408_} \\ \hline \end{tabular}
\end{table} 
Table 1: Genes associated with IRDs. To date, there is still no cure for IRDs. Furthermore, the development of a single approach is not feasible due to the heterogeneity (age of onset, speed and severity of progression, cell type predominantly affected, type of cellular dysfunction) of each disorder. Although pharmacological molecules have been developed to slow disease progression, they do not constitute a real solution [9]. However, the monogenic nature of IRDs lends them to the development of gene-based therapies. Along this line, the retina has several key characteristics that render it as an ideal tissue for this type of therapy [10].